The FDA issued draft guidance aimed at how sponsors should develop and submit biologics license applications for individualized human genome editing products designed for rare genetic diseases. In a public comment process running through November 27, the agency described considerations for BLA submission and postapproval management. A key element of the draft framework is the Individualized Feature Space (IFS), intended to define allowable variation ranges for genome-edited components across patients without requiring additional clinical trials, while keeping the therapy within a single BLA scope. The guidance provides an example centered on variable gRNA spacer sequences targeting defined classes of pathogenic variants that yield the same editing outcome. Equity and research analysts framed the draft as supportive, noting that gene editing companies have recently underperformed but may see de-risking progress alongside regulatory catalysts. The guidance also explicitly ties the regulatory approach to the reality that individualized genome editing can vary from patient to patient while remaining within a controlled product definition. For developers building next-generation editing programs, the draft suggests a more structured pathway for managing individualized variation—potentially lowering submission friction and clarifying expectations for downstream safety monitoring.